J. Foley

发表

Hi‐Fi SELEX: A high‐fidelity digital‐PCR based therapeutic aptamer discovery platform

E. Conway, C. Haynes, E. Ouellet, 2015, Biotechnology and bioengineering.

Fibrinogen as a Hemostatic Agent

B. Sørensen, J. Foley, O. H. Larsen, 2012, Seminars in Thrombosis & Hemostasis.

Procoagulant activity in stored units of red blood cells.

S. Butenas, J. Foley, Maya Aleshnick, 2016, Biochemical and biophysical research communications.

Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.

T. Orfeo, S. Butenas, J. Foley, 2012, Thrombosis research.

Impaired platelet‐dependent thrombin generation associated with thrombocytopenia is improved by prothrombin complex concentrates in vitro

D. Slatter, A. Gatt, K. Gomez, 2020, Research and practice in thrombosis and haemostasis.

FXIII: mechanisms of action in the treatment of hemophilia A

B. Sørensen, J. Foley, C. Rea, 2014, Journal of thrombosis and haemostasis : JTH.

An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A

D. Bevan, B. Sørensen, J. Foley, 2014, Annals of Hematology.

Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A

J. Ingerslev, B. Sørensen, J. Foley, 2011, Journal of thrombosis and haemostasis : JTH.

Insights into thrombin activatable fibrinolysis inhibitor function and regulation

A. Gils, J. Foley, N. Mutch, 2013, Journal of thrombosis and haemostasis : JTH.

Characteristics of fibrin formation and clot stability in individuals with congenital type IIb protein C deficiency.

K. Brummel-Ziedins, J. Foley, L. Ferris, 2012, Thrombosis research.

Soluble thrombomodulin partially corrects the premature lysis defect in FVIII‐deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor

J. Foley, M. Nesheim, 2009, Journal of thrombosis and haemostasis : JTH.

Basic weapons to degrade C3a and C5a

J. Foley, E. Conway, Edward M. Conway, 2018, Journal of thrombosis and haemostasis : JTH.

Interplay between fibrinolysis and complement: plasmin cleavage of iC3b modulates immune responses

E. Conway, J. Foley, L. Wan, 2015, Journal of thrombosis and haemostasis : JTH.

Measuring the mechanical properties of blood clots formed via the tissue factor pathway of coagulation.

K. Mann, S. Butenas, J. Foley, 2012, Analytical biochemistry.

Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD.

J. Foley, M. Nesheim, D. Owczarek, 2012, Journal of Crohn's & colitis.

Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A

G. Rivard, J. Foley, M. Nesheim, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Liver-Directed AAV Gene Therapy for Gaucher Disease

Rose M. Sheridan, R. Corbau, E. Chisari, 2019, Blood.

Cross Talk Pathways Between Coagulation and Inflammation.

E. Conway, J. Foley, 2016, Circulation research.

Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin

E. Conway, A. Wolberg, J. Foley, 2016, EBioMedicine.

From Principle to Practice: Bridging the Gap in Patient Profiling

T. Orfeo, K. Mann, S. Everse, 2013, PloS one.

Differences in wild-type– and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies

I. Yu, R. Corbau, S. Kitchen, 2022, Blood advances.

Solulin increases clot stability in whole blood from humans and dogs with hemophilia.

D. Lillicrap, B. Sørensen, J. Foley, 2012, Blood.

Factor XIII in the treatment of hemophilia A.

B. Sørensen, J. Foley, C. Rea, 2012, The New England journal of medicine.

Kinetics of Activated Thrombin-activatable Fibrinolysis Inhibitor (TAFIa)-catalyzed Cleavage of C-terminal Lysine Residues of Fibrin Degradation Products and Removal of Plasminogen-binding Sites*

P. Cook, J. Foley, M. Nesheim, 2011, The Journal of Biological Chemistry.

Modulation of complement activation and amplification on nanoparticle surfaces by glycopolymer conformation and chemistry.

E. Conway, J. Kizhakkedathu, J. Foley, 2014, ACS nano.

Plasmin(ogen) at the Nexus of Fibrinolysis, Inflammation, and Complement

J. Foley, 2017, Seminars in Thrombosis and Hemostasis.

Increased production and secretion of HGF α‐chain and an antagonistic HGF fragment in a human breast cancer progression model

Z. Jia, B. Elliott, F. Miller, 2009, International journal of cancer.

Polyphosphate suppresses complement via the terminal pathway.

N. Strynadka, E. Conway, J. Foley, 2014, Blood.

THROMBOSIS AND HEMOSTASIS Polyphosphate suppresses complement via the terminal pathway

N. Strynadka, E. Conway, J. Foley, 2014 .

Examining coagulation-complement crosstalk: complement activation and thrombosis.

J. Foley, 2016, Thrombosis research.

An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma.

J. Foley, M. Nesheim, P. Kim, 2008, Analytical biochemistry.

Modulation of inflammatory and hemostatic markers in obstructive sleep apnea patients treated with mandibular advancement splints: a parallel, controlled trial.

E. Nizankowska-Mogilnicka, A. Kania, P. Nastalek, 2014, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

Thrombin-activable Fibrinolysis Inhibitor Zymogen Does Not Play a Significant Role in the Attenuation of Fibrinolysis*

J. Foley, M. Nesheim, P. Kim, 2008, Journal of Biological Chemistry.

Gas6 gains entry into the coagulation cascade.

E. Conway, J. Foley, 2013, Blood.

Assembly of alternative prothrombinase by extracellular histones initiate and disseminate intravascular coagulation.

D. Lillicrap, J. Foley, C. Toh, 2020, Blood.

Activated thrombin activatable fibrinolysis inhibitor ( TAFIa ) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD

J. Foley, M. Nesheim, D. Owczarek, 2012 .

Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD.

J. Foley, M. Nesheim, D. Owczarek, 2012, Journal of Crohn's & colitis.

From Principle to Practice: Bridging the Gap in Patient Profiling

T. Orfeo, K. Mann, S. Everse, 2013, PloS one.

A Quantitative and Mechanistic Assessment of Activated Thrombin- Activatable Fibrinolysis Inhibitor and its Role in Pathological Bleeding and Thrombosis

J. Foley, 2010 .

Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD.

J. Foley, M. Nesheim, D. Owczarek, 2012, Journal of Crohn's & colitis.